7- (4- (3- (1H- inden- 3- yl)propyl)piperazin- 1- yl)- 1,3- benzoxazol- 2(3H)- one

structure in first source

Also Known As:

WS 50030; WS-50030; WS50030

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzoxazoles: 68
      - 7-(4-(3-(1H-inden-3-yl)propyl)piperazin-1-yl)-1,3-benzoxazol-2(3H)-one: 1
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Indenes: 4
        7-(4-(3-(1H-inden-3-yl)propyl)piperazin-1-yl)-1,3-benzoxazol-2(3H)-one: 1
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Indenes: 4
    - 7-(4-(3-(1H-inden-3-yl)propyl)piperazin-1-yl)-1,3-benzoxazol-2(3H)-one: 1

Experts

1.	Beyer, Chad E: 1 article (01/2010)
2.	Brennan, Julie A: 1 article (01/2010)
3.	Broqua, Pierre: 1 article (01/2010)
4.	Feenstra, Rolf W: 1 article (01/2010)
5.	Goutier, Wouter: 1 article (01/2010)
6.	Graf, Radka: 1 article (01/2010)
7.	Grauer, Steven M: 1 article (01/2010)
8.	Hughes, Zoë A: 1 article (01/2010)
9.	Kruse, Chris: 1 article (01/2010)
10.	Lai, Margaret: 1 article (01/2010)

Related Diseases

1.	Treatment-Resistant Depressive Disorder 01/01/2010 - "Despite possessing serotonin reuptake inhibitory activity in addition to D(2) receptor partial agonism, WS-50030 displays activity in preclinical models predictive of antipsychotic- and antidepressant efficacy similar to aripiprazole, suggesting potential efficacy of WS-50030 versus positive and negative symptoms of schizophrenia, comorbid mood symptoms, bipolar disorder, major depressive disorder, and treatment-resistant depression. "
2.	Schizophrenia (Dementia Praecox) 01/01/2010 - "Despite possessing serotonin reuptake inhibitory activity in addition to D(2) receptor partial agonism, WS-50030 displays activity in preclinical models predictive of antipsychotic- and antidepressant efficacy similar to aripiprazole, suggesting potential efficacy of WS-50030 versus positive and negative symptoms of schizophrenia, comorbid mood symptoms, bipolar disorder, major depressive disorder, and treatment-resistant depression. "
3.	Major Depressive Disorder (Major Depressive Disorders) 01/01/2010 - "Despite possessing serotonin reuptake inhibitory activity in addition to D(2) receptor partial agonism, WS-50030 displays activity in preclinical models predictive of antipsychotic- and antidepressant efficacy similar to aripiprazole, suggesting potential efficacy of WS-50030 versus positive and negative symptoms of schizophrenia, comorbid mood symptoms, bipolar disorder, major depressive disorder, and treatment-resistant depression. "
4.	Bipolar Disorder (Manic Depressive Psychosis) 01/01/2010 - "Despite possessing serotonin reuptake inhibitory activity in addition to D(2) receptor partial agonism, WS-50030 displays activity in preclinical models predictive of antipsychotic- and antidepressant efficacy similar to aripiprazole, suggesting potential efficacy of WS-50030 versus positive and negative symptoms of schizophrenia, comorbid mood symptoms, bipolar disorder, major depressive disorder, and treatment-resistant depression. "
5.	Catalepsy 01/01/2010 - "Consistent with this in vitro profile, WS-50030 (10 mg/kg/day, 21 days) significantly increased extracellular 5-HT in the rat medial prefrontal cortex, short-term WS-50030 treatment blocked apomorphine-induced climbing (ID(50), 0.51 mg/kg) in a dose range that produced minimal catalepsy in mice and induced low levels of contralateral rotation in rats with unilateral substantia nigra 6-hydroxydopamine lesions (10 mg/kg i.p.), a behavioral profile similar to that of the D(2) partial agonist aripiprazole. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Serotonin (5 Hydroxytryptamine)
3.	Antidepressive Agents (Antidepressants)
4.	Aripiprazole (Abilify)
5.	Oxidopamine (6 Hydroxydopamine)
6.	Apomorphine